The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA

Published:2022-10 Issue: Volume:65 Page:116-123
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Liu Binliang^ORCID,Hu Zheyu,Ran Jialu,Xie Ning,Tian Can,Tang Yu,Ouyang Quchang

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference29 articles.

1. The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections;Byers;CA Cancer J Clin,2016

2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

3. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy;Boonstra;Cancer Metast Rev,2020

4. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial;Hrebien;Ann Oncol,2019

5. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients;Cheng;Int J Cancer,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving value assessment of cancer therapies: Results from a modified Delphi study;Health Policy OPEN;2024-12

2. Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine;Current Opinion in Oncology;2024-07-16

3. Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression;Molecular Oncology;2024-06-12

4. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers;JCO Precision Oncology;2024-05

5. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project;JCO Precision Oncology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3